BioMarin Pharmaceutical Profit Margin

The latest profit margin for BM8.DE is 2.14% as of June 2026. That compares with 14.48% in the prior-year period — down 85.2% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside BioMarin Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, BM8.DE's profit margin moved from 14.48% to 2.14% — a 85.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioMarin Pharmaceutical's valuation or profitability profile.

Against Healthcare companies, BM8.DE currently prints 2.14% for profit margin, while the sector average sits near 9.71%. That is roughly 77.9% below the sector mean. Large gaps often invite a closer look at BioMarin Pharmaceutical's growth, margins, and balance sheet.

Profit Margin shows how effectively BioMarin Pharmaceutical converts resources into returns. At 2.14%, BM8.DE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 14.48% in the prior-year period — down 85.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BM8.DE's profit margin (2.14%), review year-over-year change from 14.48%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.